Want to see PRQR full AI Analyst Report?
PRQR Stock Chart & Stats
$1.99
-$0.10(-3.77%)
At close: 4:00 PM EST
$1.99
-$0.10(-3.77%)
Day’s Range― - ―
52-Week Range$1.33 - $3.10
Previous CloseN/A
Volume75.97K
Average Volume (3M)1.25M
Market Cap
$234.75M
Enterprise Value$93.03
Total Cash (Recent Filing)$81.17M
Total Debt (Recent Filing)$13.70M
Price to Earnings (P/E)―
Beta2.25
Next Earnings
Jul 30, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding138,087,650
10 Day Avg. Volume1,127,385
30 Day Avg. Volume1,252,745
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)3.67
Price to Sales (P/S)11.85
P/FCF Ratio-3.50
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.80Price Target Upside342.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.48
Revenue Forecast (FY)$13.41M
Bulls Say, Bears Say
Bulls Say
Axiomer Clinical ValidationClinical validation of AX-0810 demonstrates the Axiomer RNA editing platform works in humans with dose-dependent target engagement, sustained half-life and a favorable safety profile. This materially de-risks the platform, supports pipeline advancement and strengthens long-term partner and investor confidence.
Strategic Financing & Partner SupportThe combined underwritten offering and Lilly private placement bolsters cash runway and signals strategic partner conviction. Lilly’s pro rata participation and standstill commitments provide capital stability and a collaborative alignment that supports continued clinical development and potential co-development pathways.
Experienced Governance & R&D Scale-upAdding seasoned drug-development leadership to the board and enhancing AI-enabled discovery increases institutional know-how and R&D productivity. Improved governance and technology partnerships raise the company’s ability to translate platform science into clinic-ready candidates over the medium term.
Bears Say
Cash BurnSustained negative operating and free cash flow means the company cannot self-fund development and will need external financing to reach key mid-to-late stage milestones. Persistent cash burn increases dilution risk and compresses optionality for pursuing multiple programs simultaneously.
Revenue Decline & No Product SalesA declining top line and absence of commercial product revenue highlight dependence on milestone and partnership payments. This makes sustained investment and long-term growth contingent on successful clinical readouts and partner deals rather than recurring sales, raising execution risk.
Equity Erosion & Financing RelianceDeclining shareholders' equity alongside recurring equity raises signals balance-sheet erosion and ongoing reliance on dilutive financing. While leverage is moderate, repeated capital raises can dilute existing holders and constrain long-term financial flexibility if development timelines slip.
ProQR News
PRQR FAQ
What was ProQR Therapeutics BV’s price range in the past 12 months?
ProQR Therapeutics BV lowest stock price was $1.33 and its highest was $3.10 in the past 12 months.
What is ProQR Therapeutics BV’s market cap?
ProQR Therapeutics BV’s market cap is $234.75M.
When is ProQR Therapeutics BV’s upcoming earnings report date?
ProQR Therapeutics BV’s upcoming earnings report date is Jul 30, 2026 which is in 9 days.
How were ProQR Therapeutics BV’s earnings last quarter?
ProQR Therapeutics BV released its earnings results on May 12, 2026. The company reported -$0.148 earnings per share for the quarter, missing the consensus estimate of -$0.137 by -$0.011.
Is ProQR Therapeutics BV overvalued?
According to Wall Street analysts ProQR Therapeutics BV’s price is currently Undervalued.
Does ProQR Therapeutics BV pay dividends?
ProQR Therapeutics BV does not currently pay dividends.
What is ProQR Therapeutics BV’s EPS estimate?
ProQR Therapeutics BV’s EPS estimate is -0.13.
How many shares outstanding does ProQR Therapeutics BV have?
ProQR Therapeutics BV has 138,087,650 shares outstanding.
What happened to ProQR Therapeutics BV’s price movement after its last earnings report?
ProQR Therapeutics BV reported an EPS of -$0.148 in its last earnings report, missing expectations of -$0.137. Following the earnings report the stock price went down -0.621%.
Which hedge fund is a major shareholder of ProQR Therapeutics BV?
Currently, no hedge funds are holding shares in PRQR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProQR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.80 (342.21% Upside)
$8.80 (342.21% Upside)
Blogger Sentiment
Bullish
PRQR Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 91.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $469.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-30.36%
Trailing 12-Months
Company Description
ProQR Therapeutics BV
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
PRQR Stock 12 Month Forecast
Average Price Target
$8.80
▲(342.21% Upside)
Technical Analysis
Ownership Overview
0.22% Insiders
1.41% Mutual Funds
17.83% Other Institutional Investors
80.26% Public Companies and
Individual Investors